(Q43268895)

17 November 2017

title

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients (English)

1 reference

17 November 2017

1 reference

12

1 reference

17 November 2017

E Pautas

1

1 reference

17 November 2017

C Moreau

2

1 reference

17 November 2017

I Gouin-Thibault

3

1 reference

17 November 2017

J-L Golmard

4

1 reference

17 November 2017

I Mahé

5

1 reference

17 November 2017

C Legendre

6

1 reference

17 November 2017

E Taillandier-Hériche

7

1 reference

17 November 2017

B Durand-Gasselin

8

1 reference

17 November 2017

A-M Houllier

9

1 reference

17 November 2017

P Verrier

10

1 reference

17 November 2017

P Beaune

11

1 reference

17 November 2017

V Siguret

13

1 reference

17 November 2017

language of work or name

English

0 references

publication date

30 September 2009

1 reference

Clinical Pharmacology & Therapeutics

17 November 2017

published in

1 reference

17 November 2017

volume

87

1 reference

17 November 2017

issue

1

1 reference

17 November 2017

page(s)

57-64

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Estimation of height and body mass index from demi-span in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacoepigenetics: its role in interindividual differences in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Validation of the Cumulative Illness Rating Scale in a geriatric residential population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

The elderly--a challenge for appropriate drug treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.178

1 reference

Dimensions Publication ID

17 November 2017

1023843397

0 references

1 reference